Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 106 U/m2 alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 106 U/m2 of alpha-2 interferon 3 times weekly and 25 mg/m2 of cisplatinum once weekly.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Biological Response Modifiers|
|State||Published - Jan 1 1989|
All Science Journal Classification (ASJC) codes
- Cancer Research